Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 3/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.43 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121846 | 0.85 | KDM4E (0.62) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5121684 | 0.85 | NPC1 (0.45) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5123552 | 0.84 | SMN1; SMN2 (0.61) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5129249 | 0.83 | ERCC1 (0.53) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5114712 | 0.83 | POLB (0.53) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5139628 | 0.82 | LMNA (0.63) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5113712 | 0.81 | SMN1; SMN2 (0.47) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5121455 | 0.81 | ALDH1A1 (0.50) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL5129513 | 0.81 | KMT2A (0.64) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL5127644 | 0.81 | POLB (0.43) | KDM4ENPC1ALDH1A1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| EP-1441734-B1 | DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-02-28 | — | — | EP | disclosed |
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | KDM4E 414/4885NPC1 2830/4885ALDH1A1 1079/4885 |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | KDM4E 337/4885NPC1 3019/4885ALDH1A1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.